Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verastem, Inc.VSTM · Entity 5242 | Director | May 21, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verastem, Inc.
Report date May 21, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 108,000 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 108,000 · Balance 108,000 F1: 36,000 restricted stock units granted to the Reporting Person as an annual grant under the Issuer's Amended and Restated 2021 Equity Incentive Plan ("Annual Grant RSUs"). Each Annual Grant RSU represents the contingent right to receive one share of Common Stock. The Annual Grant RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. F2: 72,000 restricted stock units granted to the Reporting Person as an initial grant under the Issuer's Amended and Restated 2021 Equity Incentive Plan ("Initial Grant RSUs"). Each Initial Grant RSU represents the contingent right to receive one share of Common Stock. The Initial Grant RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) on each quarterly anniversary of May 21, 2026 (the "Start Date") until the award is fully vested on the date that is three (3) years from the Start Date, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 36,000 restricted stock units granted to the Reporting Person as an annual grant under the Issuer's Amended and Restated 2021 Equity Incentive Plan ("Annual Grant RSUs"). Each Annual Grant RSU represents the contingent right to receive one share of Common Stock. The Annual Grant RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
F2: 72,000 restricted stock units granted to the Reporting Person as an initial grant under the Issuer's Amended and Restated 2021 Equity Incentive Plan ("Initial Grant RSUs"). Each Initial Grant RSU represents the contingent right to receive one share of Common Stock. The Initial Grant RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) on each quarterly anniversary of May 21, 2026 (the "Start Date") until the award is fully vested on the date that is three (3) years from the Start Date, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVEO PHARMACEUTICALS, INC.
Report date January 19, 2023 · Filed January 19, 2023
Section 16 reporting ended · disclosed 2023-01-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 1
1 source rowRow 1 · 2023-01-19 · Disposition to issuer · Disposed 333,167 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.20 · Expires 2023-01-24 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-19 · Disposition to issuer · Disposed 3,249 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.10 · Expires 2023-06-26 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-19 · Disposition to issuer · Disposed 11,999 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2024-01-29 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-19 · Disposition to issuer · Disposed 7,499 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.40 · Expires 2025-01-06 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-01-19 · Disposition to issuer · Disposed 90,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 · Expires 2026-01-07 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-01-19 · Disposition to issuer · Disposed 46,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2027-02-07 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-01-19 · Disposition to issuer · Disposed 75,366 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.80 · Expires 2028-02-01 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-01-19 · Disposition to issuer · Disposed 99,999 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2024-06-19 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-01-19 · Disposition to issuer · Disposed 16,750 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.20 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-01-19 · Disposition to issuer · Disposed 93,500 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2030-02-05 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-01-19 · Disposition to issuer · Disposed 35,302 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12 · Expires 2031-02-05 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-01-19 · Disposition to issuer · Disposed 275,100 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.67 · Expires 2032-02-15 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-01-19 · Disposition to issuer · Disposed 625,192 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.
F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 27, 2026 21:45 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 108,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-067048 · tm2615478-6_4seq1.xml · nonDerivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,000 F1 · shares: 36,000 restricted stock units granted to the Reporting Person as an annual grant under the Issuer's Amended and Restated 2021 Equity Incentive Plan ("Annual Grant RSUs"). Each Annual Grant RSU represents the contingent right to receive one share of Common Stock. The Annual Grant RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. F2 · shares: 72,000 restricted stock units granted to the Reporting Person as an initial grant under the Issuer's Amended and Restated 2021 Equity Incentive Plan ("Initial Grant RSUs"). Each Initial Grant RSU represents the contingent right to receive one share of Common Stock. The Initial Grant RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) on each quarterly anniversary of May 21, 2026 (the "Start Date") until the award is fully vested on the date that is three (3) years from the Start Date, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 625,192 | Not disclosed Strike: $3.67 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 13 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625,192 shares Expires 2032-02-15 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 275,100 | Not disclosed Strike: $9.12 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 12 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 275,100 shares Expires 2031-02-05 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,302 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 11 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,302 shares Expires 2030-02-05 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 93,500 | Not disclosed Strike: $6.20 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 10 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,500 shares Expires 2029-02-06 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,750 | Not disclosed Strike: $15.70 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 9 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,750 shares Expires 2024-06-19 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 99,999 | Not disclosed Strike: $30.80 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 8 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,999 shares Expires 2028-02-01 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,366 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 7 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,366 shares Expires 2027-02-07 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,000 | Not disclosed Strike: $10.80 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 6 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,000 shares Expires 2026-01-07 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 90,000 | Not disclosed Strike: $8.40 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 5 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2025-01-06 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,499 | Not disclosed Strike: $17.70 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 4 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,499 shares Expires 2024-01-29 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,999 | Not disclosed Strike: $25.10 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 3 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,999 shares Expires 2023-06-26 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,249 | Not disclosed Strike: $77.20 | Not disclosed |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · derivative · entry 2 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,249 shares Expires 2023-01-24 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerCommon Stock | 333,167 | $15.00 | $4,997,505.00 |
DisclosureSEC source: 0000899243-23-002183 · doc4.xml · nonDerivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:46 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Exercise / conversionStock Option (right to buy) · Derivative | 164,525 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001628280-22-032490 · wf-form4_167174557174898.xml · derivative · entry 6 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,192 Underlying: Common Stock · 164,525 shares Expires 2032-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 15, 2022 through February 15, 2026, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:46 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Exercise / conversionStock Option (right to buy) · Derivative | 85,722 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001628280-22-032490 · wf-form4_167174557174898.xml · derivative · entry 5 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,302 Underlying: Common Stock · 85,722 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 5, 2020 through February 5, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:46 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Exercise / conversionStock Option (right to buy) · Derivative | 26,499 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001628280-22-032490 · wf-form4_167174557174898.xml · derivative · entry 4 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,500 Underlying: Common Stock · 26,499 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:46 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Exercise / conversionCommon Stock | 164,525 | $3.67 | $603,806.75 |
DisclosureSEC source: 0001628280-22-032490 · wf-form4_167174557174898.xml · nonDerivative · entry 3 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:46 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Exercise / conversionCommon Stock | 85,722 | $5.60 | $480,043.20 |
DisclosureSEC source: 0001628280-22-032490 · wf-form4_167174557174898.xml · nonDerivative · entry 2 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:46 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Exercise / conversionCommon Stock | 26,499 | $6.20 | $164,293.80 |
DisclosureSEC source: 0001628280-22-032490 · wf-form4_167174557174898.xml · nonDerivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,110 shares purchased by the Reporting Person under the Company's 2010 Employee Stock Purchase Plan, as amended. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:58 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 789,717 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001628280-22-003055 · wf-form4_164513508741973.xml · derivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789,717 Underlying: Common Stock · 789,717 shares Expires 2032-02-15 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 15, 2022 through February 15, 2026, subject to the Reporting Person's continued service to the Company. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 17:12 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | PurchaseCommon Stock | 15,000 | $6.48 | $97,200.00 |
DisclosureSEC source: 0000899243-21-035140 · doc4.xml · nonDerivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,311 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.49, inclusive. The reporting person undertakes to provide to AVEO, any security holder of AVEO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F2 · balance_after: Includes 2,426 shares acquired under AVEO's 2010 Employee Stock Purchase Plan. Read SEC document |
| February 05, 2021 Filed Apr 16, 2021 16:05 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $9.12 | $0.00 |
DisclosureSEC source: 0000899243-21-016106 · doc4.xml · derivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-02-05 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 5, 2021 through February 5, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 17:43 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 1,210,250 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0000899243-20-003702 · doc4.xml · derivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210,250 Underlying: Common Stock · 1,210,250 shares Expires 2030-02-05 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 5, 2020 through February 5, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 16:30 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | PurchaseCommon Stock | 150,000 | $0.60 | $89,595.00 |
DisclosureSEC source: 0000899243-19-028068 · doc4.xml · nonDerivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,848 Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:30 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 1,200,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-19-003033 · doc4.xml · derivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires 2029-02-06 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:10 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000899243-18-002757 · doc4.xml · derivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 1, 2018, through February 1, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 21, 2017 Filed Jun 28, 2017 17:10 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 188,666 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000899243-17-017408 · doc4.xml · derivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,666 Underlying: Common Stock · 188,666 shares Expires 2027-02-07 F1 · derivative.exercise_date: On Febuary 8, 2017, the reporting person was granted an option to purchase 283,000 shares of common stock. Subject to the achievement of three performance milestones relating to the company's clinical trials and regulatory filings, one third of the option vests on February 8, 2018, and two thirds of the option vests on February 8, 2019. On June 21, 2017, the first two performance milestones were met. As a result, one third of the option will vest on February 8, 2018, and one third of the option will vest on February 8, 2019, in each case subject to the reporting person's continued service to the company. F1 · balance_after: On Febuary 8, 2017, the reporting person was granted an option to purchase 283,000 shares of common stock. Subject to the achievement of three performance milestones relating to the company's clinical trials and regulatory filings, one third of the option vests on February 8, 2018, and two thirds of the option vests on February 8, 2019. On June 21, 2017, the first two performance milestones were met. As a result, one third of the option will vest on February 8, 2018, and one third of the option will vest on February 8, 2019, in each case subject to the reporting person's continued service to the company. Read SEC document |
| March 28, 2017 Filed Mar 30, 2017 21:27 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | OtherCommon Stock | 100,000 | $0.50 | $50,000.00 |
DisclosureSEC source: 0000899243-17-008971 · doc4.xml · nonDerivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,848 F1 · kind: Reports the purchase of shares in the underwritten public offering of common stock of AVEO Pharmaceuticals, Inc. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:22 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 565,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000899243-17-003468 · doc4.xml · derivative · entry 1 BAILEY MICHAEL P · CIK 0001255856 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,000 Underlying: Common Stock · 565,000 shares Expires 2027-02-07 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 8, 2017, through February 8, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.